Compare WVE & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | EXG |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.0B |
| IPO Year | 2015 | 2006 |
| Metric | WVE | EXG |
|---|---|---|
| Price | $13.35 | $9.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $31.47 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 475.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.28 | $6.74 |
| 52 Week High | $21.73 | $9.78 |
| Indicator | WVE | EXG |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 27.05 |
| Support Level | $12.53 | $8.93 |
| Resistance Level | $14.56 | $9.34 |
| Average True Range (ATR) | 0.79 | 0.11 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 23.84 | 3.62 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.